These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
173 related articles for article (PubMed ID: 34113545)
41. Biomarkers in patients with mucopolysaccharidosis type II and IV. Fujitsuka H; Sawamoto K; Peracha H; Mason RW; Mackenzie W; Kobayashi H; Yamaguchi S; Suzuki Y; Orii K; Orii T; Fukao T; Tomatsu S Mol Genet Metab Rep; 2019 Jun; 19():100455. PubMed ID: 30775257 [TBL] [Abstract][Full Text] [Related]
42. Odiparcil, a potential glycosaminoglycans clearance therapy in mucopolysaccharidosis VI-Evidence from in vitro and in vivo models. Entchev E; Jantzen I; Masson P; Bocart S; Bournique B; Luccarini JM; Bouchot A; Lacombe O; Junien JL; Broqua P; Tallandier M PLoS One; 2020; 15(5):e0233032. PubMed ID: 32413051 [TBL] [Abstract][Full Text] [Related]
43. Elosulfase alfa for mucopolysaccharidosis type IVA: Real-world experience in 7 patients from the Spanish Morquio-A early access program. Pintos-Morell G; Blasco-Alonso J; Couce ML; Gutiérrez-Solana LG; Guillén-Navarro E; O'Callaghan M; Del Toro M Mol Genet Metab Rep; 2018 Jun; 15():116-120. PubMed ID: 30023300 [TBL] [Abstract][Full Text] [Related]
44. The effectiveness of enzyme replacement therapy on cardiac findings in patients with mucopolysaccharidosis. Bilginer Gurbuz B; Aypar E; Coskun T; Alehan D; Dursun A; Tokatli A; Sivri HS J Pediatr Endocrinol Metab; 2019 Oct; 32(10):1049-1053. PubMed ID: 31469658 [TBL] [Abstract][Full Text] [Related]
45. Activity of daily living in mucopolysaccharidosis IVA patients: Evaluation of therapeutic efficacy. Chen H; Khan S; Celik B; Suzuki Y; Ago Y; Tomatsu S Mol Genet Genomic Med; 2021 Nov; 9(11):e1806. PubMed ID: 34623762 [TBL] [Abstract][Full Text] [Related]
46. Effect of enzyme replacement therapy on the growth of patients with Morquio A. Doherty C; Stapleton M; Piechnik M; Mason RW; Mackenzie WG; Yamaguchi S; Kobayashi H; Suzuki Y; Tomatsu S J Hum Genet; 2019 Jul; 64(7):625-635. PubMed ID: 31019230 [TBL] [Abstract][Full Text] [Related]
47. Urinary glycosaminoglycans as a potential biomarker for evaluating treatment efficacy in subjects with mucopolysaccharidoses. Kakkis E; Marsden D Mol Genet Metab; 2020 May; 130(1):7-15. PubMed ID: 32224020 [TBL] [Abstract][Full Text] [Related]
48. Review of clinical presentation and diagnosis of mucopolysaccharidosis IVA. Hendriksz CJ; Harmatz P; Beck M; Jones S; Wood T; Lachman R; Gravance CG; Orii T; Tomatsu S Mol Genet Metab; 2013; 110(1-2):54-64. PubMed ID: 23665161 [TBL] [Abstract][Full Text] [Related]
49. Oxidative profile exhibited by Mucopolysaccharidosis type IVA patients at diagnosis: Increased keratan urinary levels. Donida B; Marchetti DP; Jacques CED; Ribas G; Deon M; Manini P; da Rosa HT; Moura DJ; Saffi J; Giugliani R; Vargas CR Mol Genet Metab Rep; 2017 Jun; 11():46-53. PubMed ID: 28487826 [TBL] [Abstract][Full Text] [Related]
50. Elosulfase alfa in the treatment of mucopolysaccharidosis type IVA: insights from the first managed access agreement. Stevens B; Kenny T; Thomas S; Morrison A; Jarrett J; Jain M Orphanet J Rare Dis; 2021 Sep; 16(1):394. PubMed ID: 34563214 [TBL] [Abstract][Full Text] [Related]
54. Effect of enzyme replacement therapy on bone formation in a feline model of mucopolysaccharidosis type VI. Byers S; Nuttall JD; Crawley AC; Hopwood JJ; Smith K; Fazzalari NL Bone; 1997 Nov; 21(5):425-31. PubMed ID: 9356736 [TBL] [Abstract][Full Text] [Related]
55. Clinical features and health-related quality of life in adult patients with mucopolysaccharidosis IVA: the Spanish experience. Quijada-Fraile P; Arranz Canales E; Martín-Hernández E; Ballesta-Martínez MJ; Guillén-Navarro E; Pintos-Morell G; Moltó-Abad M; Moreno-Martínez D; García Morillo S; Blasco-Alonso J; Couce ML; Gil Sánchez R; Cortès-Saladelafont E; López Rodríguez MA; García-Silva MT; Morales Conejo M Orphanet J Rare Dis; 2021 Nov; 16(1):464. PubMed ID: 34732228 [TBL] [Abstract][Full Text] [Related]
56. Incidence of the mucopolysaccharidoses in Western Australia. Nelson J; Crowhurst J; Carey B; Greed L Am J Med Genet A; 2003 Dec; 123A(3):310-3. PubMed ID: 14608657 [TBL] [Abstract][Full Text] [Related]
57. Data in support of the longitudinal characterization of pulmonary function in children with Mucopolysaccharidoses IVA. Kenth JJ; Thompson G; Wilkinson S; Jones S; Bruce IA Data Brief; 2019 Dec; 27():104756. PubMed ID: 31886335 [TBL] [Abstract][Full Text] [Related]
58. Mucopolysaccharidosis type VI: case report with first neonatal presentation with ascites fetalis and rapidly progressive cardiac manifestation. Honjo RS; Vaca ECN; Leal GN; Abellan DM; Ikari NM; Jatene MB; Martins AM; Kim CA BMC Med Genet; 2020 Feb; 21(1):37. PubMed ID: 32075597 [TBL] [Abstract][Full Text] [Related]
59. Diagnostic and treatment strategies in mucopolysaccharidosis VI. Vairo F; Federhen A; Baldo G; Riegel M; Burin M; Leistner-Segal S; Giugliani R Appl Clin Genet; 2015; 8():245-55. PubMed ID: 26586959 [TBL] [Abstract][Full Text] [Related]
60. Development of a fluorometric microtiter plate based enzyme assay for MPS IVA (Morquio type A) using dried blood spots. Ullal AJ; Millington DS; Bali DS Mol Genet Metab Rep; 2014; 1():461-464. PubMed ID: 27896123 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]